Zobrazeno 1 - 3
of 3
pro vyhledávání: '"Kim Westerdijk"'
Autor:
Kim Westerdijk, Neeltje Steeghs, Casper S. J. Tacke, Winette T. A. van derGraaf, Nielka P. vanErp, Gerard vanOortmerssen, Rosella P. M. G. Hermens, Ingrid M. E. Desar, In collaboration with the Dutch Pharmacology Oncology Group (DPOG)
Publikováno v:
Cancer Medicine, Vol 12, Iss 22, Pp 21041-21056 (2023)
Abstract Background Personalized dosing based on measurement of individual drug levels and adjusting the dose accordingly can improve efficacy and decrease unnecessary toxicity of oncological treatment. For imatinib, sunitinib, and pazopanib, this th
Externí odkaz:
https://doaj.org/article/f526d700fa4545ab81c035bd276d9978
Autor:
Kim Westerdijk, Koen S Simons, Marissa Zegers, Peter C Wever, Peter Pickkers, Cornelis P C de Jager
Publikováno v:
PLoS ONE, Vol 14, Iss 2, p e0212861 (2019)
BACKGROUND:Early diagnosis and treatment has proven to be of utmost importance in the outcome of sepsis patients. We compared the accuracy of the neutrophil-lymphocyte count ratio (NLCR) to conventional inflammatory markers in patients admitted to th
Externí odkaz:
https://doaj.org/article/746e6148d1e34d74ad013285a633da75
Autor:
Sasja F. Mulder, Ingrid M.E. Desar, Nielka P. van Erp, Winette T. A. van der Graaf, Stefanie D. Krens, Kim Westerdijk, Carla M.L. van Herpen, Tineke J. Smilde
Publikováno v:
British Journal of Clinical Pharmacology, 87, 326-335
British Journal of Clinical Pharmacology, 87, 2, pp. 326-335
British Journal of Clinical Pharmacology, 87, 2, pp. 326-335
Contains fulltext : 232106.pdf (Publisher’s version ) (Open Access) AIM: Sunitinib is an oral tyrosine kinase inhibitor approved for the treatment of renal cell carcinoma (RCC) and gastrointestinal stromal tumor (GIST). Because of the large interpa
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::9fa3d03d4c11c0f56b890711229ff004
http://hdl.handle.net/2066/232106
http://hdl.handle.net/2066/232106
